BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 2908226)

  • 1. A Markov process based model of the neurotransmitter-receptor binding process in the brain.
    Elkarmi AZ; Karmi MZ; Alkarmi ZM
    Drug Des Deliv; 1988 Jul; 3(1):69-76. PubMed ID: 2908226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Markov process based model of the neurotransmitter-receptor binding process in the brain--comment.
    Farooqi ZH
    Drug Des Deliv; 1989 May; 4(3):257-9. PubMed ID: 2577442
    [No Abstract]   [Full Text] [Related]  

  • 3. Transmitter receptor alterations in Parkinson's disease.
    Calne DB; Stoessl AJ
    Adv Neurol; 1987; 45():45-9. PubMed ID: 2881449
    [No Abstract]   [Full Text] [Related]  

  • 4. Absolute quantification by positron emission tomography of the endogenous ligand.
    Delforge J; Bottlaender M; Pappata S; Loc'h C; Syrota A
    J Cereb Blood Flow Metab; 2001 May; 21(5):613-30. PubMed ID: 11333372
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Schizophrenia: diverse approaches to a complex disease.
    Sawa A; Snyder SH
    Science; 2002 Apr; 296(5568):692-5. PubMed ID: 11976442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potential nondopaminergic drugs for Parkinson's disease.
    Silverdale MA; Fox SH; Crossman AR; Brotchie JM
    Adv Neurol; 2003; 91():273-91. PubMed ID: 12442686
    [No Abstract]   [Full Text] [Related]  

  • 7. A continuous time version and a generalization of a Markov-recapture model for trapping experiments.
    Alpizar-Jara R; Smith CE
    Math Biosci; 2008; 214(1-2):11-9. PubMed ID: 18556026
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SAS macro program for non-homogeneous Markov process in modeling multi-state disease progression.
    Hui-Min W; Ming-Fang Y; Chen TH
    Comput Methods Programs Biomed; 2004 Aug; 75(2):95-105. PubMed ID: 15212852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Markov model for interspike interval distributions of auditory cortical neurons that do not show periodic firings.
    Britvina T; Eggermont JJ
    Biol Cybern; 2007 Feb; 96(2):245-64. PubMed ID: 17082952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling disease-state transition heterogeneity through Bayesian variable selection.
    Healy BC; Engler D
    Stat Med; 2009 Apr; 28(9):1353-68. PubMed ID: 19206077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurotransmitters and neurodegenerative disorders.
    Kanazawa I
    Clin Ther; 1984; 7 Spec No():48-58. PubMed ID: 6152198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating the neurobiology of schizophrenia. Preface.
    Abi-Dargham A; Guillin O
    Int Rev Neurobiol; 2007; 78():xiii-xvi. PubMed ID: 17349855
    [No Abstract]   [Full Text] [Related]  

  • 13. Membrane phospholipid composition, alterations in neurotransmitter systems and schizophrenia.
    du Bois TM; Deng C; Huang XF
    Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul; 29(6):878-88. PubMed ID: 16005134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A discrete-state discrete-time model using indirect observation.
    Isaman DJ; Herman WH; Brown MB
    Stat Med; 2006 Mar; 25(6):1035-49. PubMed ID: 16416413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Compared Markov with fractal models by using single-channel experimental and simulation data].
    Lan T; Wu H; Lin J
    Sheng Wu Yi Xue Gong Cheng Xue Za Zhi; 2006 Oct; 23(5):923-8. PubMed ID: 17121323
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Calibrating E-values for hidden Markov models using reverse-sequence null models.
    Karplus K; Karchin R; Shackelford G; Hughey R
    Bioinformatics; 2005 Nov; 21(22):4107-15. PubMed ID: 16123115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Neurobiological findings in schizophrenia].
    Lingjaerde O
    Tidsskr Nor Laegeforen; 2002 Sep; 122(21):2123-7. PubMed ID: 12555651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Biological psychiatry. 1) The dopamine-acetylcholine equilibrium model].
    Adèr JP
    TVZ; 1988 Jan; 42(1):13-6. PubMed ID: 2895504
    [No Abstract]   [Full Text] [Related]  

  • 19. Applications of continuous time hidden Markov models to the study of misclassified disease outcomes.
    Bureau A; Shiboski S; Hughes JP
    Stat Med; 2003 Feb; 22(3):441-62. PubMed ID: 12529874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The influence of hormones on drug-induced modifications in neurotransmitter receptor binding.
    Kendall DA; Slopis J; Duman R; Stancel GM; Enna SJ
    Prog Clin Biol Res; 1982; 79():193-207. PubMed ID: 6124004
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.